e.l.f. Beauty Releases FY2025 Impact Report with Emphasis on ‘ the Every ’
28.10.2025 06:01:00 EET | Business Wire | Press release
e.l.f. Beauty (NYSE: ELF), a purpose-led, results-driven company on a mission to make the best of beauty accessible to every eye, lip and face, today released its fourth annual Impact Report.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251027352775/en/
e.l.f. Beauty releases 4th annual Impact Report, emphasizing it’s evolved purpose statement: to make the world a better place for every eye, lip and face.
The digital-first report is built around the theme of “the every”— a reflection of e.l.f.’s commitment to be a bold disruptor with a kind heart. To amplify the message behind the Impact Report, e.l.f. also launched a bold, international consumer campaign: “Give an e.l.f.” The campaign features voices of kindred spirits and encourages the community to fuel their own sense of purpose.
“Sharing our Impact Report is one of my proudest moments each year as we see the collective highlights of living our vision to be a different kind of company by building brands that disrupt norms, shape culture and connect communities through positivity, inclusivity and accessibility,” said Tarang Amin, Chairman and CEO, e.l.f. Beauty.
The report includes an evolution of the company’s purpose statement to emphasize action and impact: to make the world a better place for every eye, lip and face.
“Our commitment to show up as bold disruptors with kind hearts has been unwavering throughout the company’s 21-year history,” Amin said. “It guides how we operate each day and why we make every one of our choices as a purpose-led, results-driven company.”
e.l.f. Beauty’s strong ethos powers its purpose, purpose powers its people, people power its performance – and performance powers its possibilities. Focusing on achievements across key areas, including People & Culture, Innovation & Community, Campaigns & Activations, and Environment & Sustainability. Key highlights reported include:
- At least 2% of the prior year’s profits – totaling more than $2.5 million in FY2025 – donated to changemaking causes that align with the company’s values, spanning boardroom diversity, animal welfare, health and wellness, women's empowerment, LGBTQ+ advocacy, disaster relief and more
- More than 140 business leaders, nonprofits and peer companies have joined e.l.f. Beauty’s Change the Board Game coalition, all committed to creating more accessible boardrooms
- 75% of e.l.f. Cosmetics products are $10 and under to maximize accessibility
- 73% of e.l.f. Beauty brands’ products are made in Fair Trade Certified facilities*
- 100% of cosmetic brushes' wood handles now use Forest Stewardship Council™-certified wood*
- Achieved a 33% reduction in packaging intensity in FY2025 versus a 2019 baseline, exceeding our 2030 goal for a 20% reduction*
The complementary campaign, created with creative agency CASE, will be featured across social, digital, print and out-of-home placements with a simple, direct call to action: “What do you give an e.l.f. (F#@&) about?” Among those giving passionate and confident answers – straight to camera – are:
- Billie Jean King, equality champion, gives an e.l.f. about board diversity representation
- Aditya Madiraju, creator, gives an e.l.f. about LGBTQIA+ advocacy
- Jaedyn Shaw, professional soccer player, gives an e.l.f. about women in sports
- Kgothatso Montjane “KG”, paralympian, gives an e.l.f. about empowering.legendary.females.
- Amanda Nguyen, astronaut and activist, gives an e.l.f. about women’s rights
- Katherine Legge, professional racecar driver, gives an e.l.f. about putting girls in the driver’s seat
- Meduulla, musician, gives an e.l.f. about amplifying voices
- Melanie Barcenas, professional soccer player, gives an e.l.f. about self-expression
- Jess Rona, dog groomer, gives an e.l.f. about cruelty-free
- Javon Ford, cosmetic chemist, gives an e.l.f. about affordable skincare made with quality ingredients
- Paul Rice, founder of Fair Trade USA, gives an e.l.f. about Fair Trade
“We all give an e.l.f. We have the courage to care and that’s how we make the world a better place for every eye, lip and face,” said Kory Marchisotto, Chief Marketing Officer, e.l.f. Beauty. “This campaign is our collective voice calling the world to stand up, speak up and show up for what matters. It’s turning caring into a cultural movement. We’re force multiplying with icons like Billie Jean King and Amanda Nguyen to inspire everyone to take action on what they give an e.l.f. about.”
The campaign will appear across more than 40 digital screens in Moynihan Train Hall at New York’s Penn Station, and will be seen as a two-page spread in The New York Times on Sunday, November 2, 2025.
e.l.f. Beauty is also hosting a live activation today at 410 Lafayette Street in New York City from 10AM – 6PM ET, where the public is invited to “give an e.l.f.” — literally and figuratively. At a custom kiosk, visitors can select a cause they care about, and e.l.f. Beauty will make a donation to a nonprofit organization focused on that cause. Participating guests will receive a printed receipt confirming the donation and are invited to take their receipt to the gift bar in exchange for e.l.f. Beauty products.
To explore the full FY2025 Impact Report and learn more about how e.l.f. Beauty is creating change, visit: elfbeauty.com/impact.
Check out the campaign trailer here.
* These metrics do not include rhode, acquired in August 2025. Fair Trade metric is calculated on a unit basis.
About e.l.f. Beauty
e.l.f. Beauty (NYSE: ELF) is fueled by a belief that anything is e.l.f.ing possible. We are a different kind of company that disrupts norms, shapes culture and connects communities through positivity, inclusivity and accessibility. The mission is clear: to make the best of beauty accessible to every eye, lip and face. e.l.f. Beauty and its brands, e.l.f. Cosmetics, e.l.f. SKIN, Keys Soulcare, Well People, Naturium and rhode, are led by purpose, driven by results and elevated by superpowers, offering e.l.f. clean and vegan products. e.l.f. Beauty proudly stands as the first beauty company with Fair Trade Certified™ facilities. With a kind heart at the center of e.l.f.’s ethos, the company donates at least 2% of the prior year’s profits to organizations that make positive impacts. Learn more at www.elfbeauty.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20251027352775/en/
Contacts
Laura Cosgrave
lcosgrave@elfbeauty.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom